These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 22348480)

  • 1. Identification of a specific inhibitor of nOGA - a caspase-3 cleaved O-GlcNAcase variant during apoptosis.
    Li J; Li Z; Li T; Lin L; Zhang Y; Guo L; Xu Y; Zhao W; Wang P
    Biochemistry (Mosc); 2012 Feb; 77(2):194-200. PubMed ID: 22348480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevation of cellular O-GlcNAcylation level by a potent and selective O-GlcNAcase inhibitor based on tetrahydroimidazopyridine scaffold.
    Li T; Li Z; Li J; Wang J; Guo L; Wang PG; Zhao W
    Bioorg Med Chem Lett; 2012 Nov; 22(22):6854-7. PubMed ID: 23058883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A divergent synthesis of 2-acyl derivatives of PUGNAc yields selective inhibitors of O-GlcNAcase.
    Stubbs KA; Zhang N; Vocadlo DJ
    Org Biomol Chem; 2006 Mar; 4(5):839-45. PubMed ID: 16493467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of PUGNAc and NAG-thiazoline as transition state analogues for human O-GlcNAcase: mechanistic and structural insights into inhibitor selectivity and transition state poise.
    Whitworth GE; Macauley MS; Stubbs KA; Dennis RJ; Taylor EJ; Davies GJ; Greig IR; Vocadlo DJ
    J Am Chem Soc; 2007 Jan; 129(3):635-44. PubMed ID: 17227027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An O-GlcNAcase-specific inhibitor and substrate engineered by the extension of the N-acetyl moiety.
    Kim EJ; Perreira M; Thomas CJ; Hanover JA
    J Am Chem Soc; 2006 Apr; 128(13):4234-5. PubMed ID: 16568991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A quantum mechanics/molecular mechanics study of the protein-ligand interaction of two potent inhibitors of human O-GlcNAcase: PUGNAc and NAG-thiazoline.
    Lameira J; Alves CN; Moliner V; Martí S; Kanaan N; Tuñón I
    J Phys Chem B; 2008 Nov; 112(45):14260-6. PubMed ID: 18939790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of GlcNAc-inspired iminocyclitiols as potent and selective N-acetyl-beta-hexosaminidase inhibitors.
    Ho CW; Popat SD; Liu TW; Tsai KC; Ho MJ; Chen WH; Yang AS; Lin CH
    ACS Chem Biol; 2010 May; 5(5):489-97. PubMed ID: 20187655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Streptozotocin-induced beta-cell death is independent of its inhibition of O-GlcNAcase in pancreatic Min6 cells.
    Gao Y; Parker GJ; Hart GW
    Arch Biochem Biophys; 2000 Nov; 383(2):296-302. PubMed ID: 11185566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dissecting PUGNAc-mediated inhibition of the pro-survival action of insulin.
    Teo CF; El-Karim EG; Wells L
    Glycobiology; 2016 Nov; 26(11):1198-1208. PubMed ID: 27072814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of O-GlcNAcase by a gluco-configured nagstatin and a PUGNAc-imidazole hybrid inhibitor.
    Shanmugasundaram B; Debowski AW; Dennis RJ; Davies GJ; Vocadlo DJ; Vasella A
    Chem Commun (Camb); 2006 Nov; (42):4372-4. PubMed ID: 17057847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insight into a strategy for attenuating AmpC-mediated beta-lactam resistance: structural basis for selective inhibition of the glycoside hydrolase NagZ.
    Balcewich MD; Stubbs KA; He Y; James TW; Davies GJ; Vocadlo DJ; Mark BL
    Protein Sci; 2009 Jul; 18(7):1541-51. PubMed ID: 19499593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. E. coli sabotages the in vivo production of O-linked β-N-acetylglucosamine-modified proteins.
    Goodwin OY; Thomasson MS; Lin AJ; Sweeney MM; Macnaughtan MA
    J Biotechnol; 2013 Dec; 168(4):315-23. PubMed ID: 24140293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Computational analysis of human OGA structure in complex with PUGNAc and NAG-thiazoline derivatives.
    de Alencar NA; Sousa PR; Silva JR; Lameira J; Alves CN; Martí S; Moliner V
    J Chem Inf Model; 2012 Oct; 52(10):2775-83. PubMed ID: 22937904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. O-GlcNAc modification on IRS-1 and Akt2 by PUGNAc inhibits their phosphorylation and induces insulin resistance in rat primary adipocytes.
    Park SY; Ryu J; Lee W
    Exp Mol Med; 2005 Jun; 37(3):220-9. PubMed ID: 16000877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinctive inhibition of O-GlcNAcase isoforms by an alpha-GlcNAc thiolsulfonate.
    Kim EJ; Amorelli B; Abdo M; Thomas CJ; Love DC; Knapp S; Hanover JA
    J Am Chem Soc; 2007 Dec; 129(48):14854-5. PubMed ID: 17994748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. O-GlcNAcase uses substrate-assisted catalysis: kinetic analysis and development of highly selective mechanism-inspired inhibitors.
    Macauley MS; Whitworth GE; Debowski AW; Chin D; Vocadlo DJ
    J Biol Chem; 2005 Jul; 280(27):25313-22. PubMed ID: 15795231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The synthesis and biological evaluation of some carbocyclic analogues of PUGNAc.
    Scaffidi A; Stubbs KA; Vocadlo DJ; Stick RV
    Carbohydr Res; 2008 Nov; 343(16):2744-53. PubMed ID: 18804755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enzymatic characterization and inhibition of the nuclear variant of human O-GlcNAcase.
    Macauley MS; Vocadlo DJ
    Carbohydr Res; 2009 Jun; 344(9):1079-84. PubMed ID: 19423084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PUGNAc treatment leads to an unusual accumulation of free oligosaccharides in CHO cells.
    Mehdy A; Morelle W; Rosnoblet C; Legrand D; Lefebvre T; Duvet S; Foulquier F
    J Biochem; 2012 Apr; 151(4):439-46. PubMed ID: 22337894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GlcNAcstatins are nanomolar inhibitors of human O-GlcNAcase inducing cellular hyper-O-GlcNAcylation.
    Dorfmueller HC; Borodkin VS; Schimpl M; van Aalten DM
    Biochem J; 2009 May; 420(2):221-7. PubMed ID: 19275764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.